Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases
- 1 June 2021
- journal article
- research article
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 134, 14-21
Abstract
No abstract availableKeywords
Funding Information
- United Therapeutics Corporation
This publication has 34 references indexed in Scilit:
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisThe Lancet, 2013
- Effect of Competition Bias in Safety Signal GenerationDrug Safety, 2012
- Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance databaseBritish Journal of Clinical Pharmacology, 2011
- Defining ‘Signal’ and its Subtypes in Pharmacovigilance Based on a Systematic Review of Previous DefinitionsDrug Safety, 2009
- Impact of Safety Alerts on Measures of Disproportionality in Spontaneous Reporting DatabasesDrug Safety, 2007
- The reporting odds ratio and its advantages over the proportional reporting ratioPharmacoepidemiology and Drug Safety, 2004
- A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactionsPharmacoepidemiology and Drug Safety, 2002
- Principles of Signal Detection in PharmacovigilanceDrug Safety, 1997
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981